AMPD3

Across TCGA pan-cancer cohorts, AMPD3 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated AMPD3 data layer compared with 27 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher AMPD3 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated AMPD3 expression acts as an unfavorable survival marker, although some lineages such as HNSC and UCEC show a favorable association.

CCRCC, COAD, and LUAD are the cancer types where AMPD3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	III,IV	0.105	0.928	.003	45	view →
COAD	DFS	Median	II,III,IV	0.877	1.000	.016	42	view →
LUAD	OS	Quartile	III,IV	0.205	0.931	<.001	29	view →
PDAC	DFS	Tertile	All	0.699	0.832	.012	20	view →
HNSC	OS	Median	All	0.801	0.626	.017	8	view →
UCEC	OS	Median	All	0.969	0.858	.043	4	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

AMPD3–CCRCC (DFS)

Open the CCRCC breakdown →